AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9578008
Drug: High-dose barbiturates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose barbiturates
Trial: 7644238
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac (1 mg/kg)
Trial: 2526633
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine (HBVax II, MSD, 5 micrograms)
Trial: 2526633
Drug: Plasma derived
RxNorm normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma derived hepatitis B vaccine (HBVax, MSD, 10 micrograms)
Trial: 136668
Drug: Mianserin hydrochloride
RxNorm normalized name: Mianserin hydrochloride
DrugBank: Mianserin (DB06148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin hydrochloride (20 mg three times daily)
Trial: 22702846
Drug: Combination etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination etanercept and NB-UVB phototherapy
Trial: 22702846
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (etanercept monotherapy and combination therapy)
Trial: 21785174
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) based intracoronary infusion of peripheral blood stem cells (PBSCs) after 5 days of G-CSF administration and EPO at the time of PBSCs injection
Trial: 19111789
Drug: Effective surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective surgical treatment costing $40,000
Trial: 16458799
Drug: Self‐reinforced poly‐L‐lactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐reinforced poly‐L‐lactic acid polymer (PLLA group, n = 20)
Trial: 11783366
Drug: GnRH‐a long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a long protocol (0.9 mg/day nasal spray starting on day 21)
Trial: 11783366
Drug: GnRH‐a short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a short protocol (0.45 mg/day nasal spray starting on day 2)
Trial: 30153359
Drug: Simtuzumab 75
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simtuzumab 75 mg
Trial: 30153359
Drug: Simtuzumab 125
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simtuzumab 125 mg
Trial: 30153359
Drug: Simtuzumab 75
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simtuzumab 75 mg and 125 mg
Trial: 28060063
Drug: 1.2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/d of a triglyceride formulation of oral omega-3 fatty acids for 12 weeks
Trial: 28060063
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d vitamin E for 12 weeks
Trial: 26209038
Drug: Glimepiride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1 mg/day) - Control
Trial: 21140383
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of EGb 761 once daily for 24 weeks
Trial: 11449954
Drug: Solvent/detergent-treated intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solvent/detergent-treated intramuscular immunoglobulin
Trial: 11449954
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular immunoglobulin
Trial: 9610964
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone (2 mg/kg for 10 min)
Trial: 3260083
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg propofol/kg per minute
Trial: 3260083
Drug: 0.10 mg
RxNorm normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg propofol/kg per minute
Trial: 3260083
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg propofol/kg per minute
Trial: 3260083
Drug: 0.20 mg
RxNorm normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg propofol/kg per minute
Trial: 26333513
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (2 g PS/d)
Trial: 18178379
Drug: Supplemented hypokinetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented hypokinetic subjects (SHKSs) with daily supplementation of 0.7 mmol of calcium lactate per kilogram of body weight
Trial: 16813479
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isotonic exercises
Trial: 12708129
Drug: Oral medication
RxNorm normalized name: Oral Medication Syringe 3mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication (Group I)
Trial: 12708129
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (Group II)
Trial: 8621989
Drug: Propranolol with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol with aspirin and/or coronary artery surgery
Trial: 8621989
Drug: Propranolol without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol without aspirin and/or coronary artery surgery
Trial: 17548693
Drug: Serum alpha‐tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum alpha‐tocopherol supplementation (50 mg daily for 5‐8 years)
Trial: 15233282
Drug: Disopyramide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (6 mg/kg)
Trial: 15233282
Drug: Mexiletine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (4 mg/kg)
Trial: 15233282
Drug: Pilsicainide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide (4 mg/kg)
Trial: 9203234
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose at endpoint: 5.9 mg/day)
Trial: 11767424
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of physiological saline injection (Group A)
Trial: 11767424
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (Group B)
Trial: 20570240
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 0.02% MMC 1 month before bare scleral excision
Trial: 18812325
Drug: Isoflavone supplement
RxNorm normalized name: Soyrel Soy Isoflavone Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplement (80 mg/day)
Trial: 16911386
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical methotrexate gel
Trial: 16911386
Drug: Placebo (vaseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vaseline ointment)
Trial: 12816908
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg THC/day)
Trial: 11053334
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg) and Theophylline (4.5 mg/kg)
Trial: 6381186
Drug: 4-amino-salicylic acid
RxNorm normalized name: para-amino salicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-amino-salicylic acid (4-ASA) enemas (1 g)
Trial: 6381186
Drug: 4-amino-salicylic acid
RxNorm normalized name: para-amino salicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-amino-salicylic acid (4-ASA) enemas (2 g)
Trial: 31390900
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management program (weekly group-based sessions over an 8-week period)
Trial: 21510527
Drug: Injection clonidine
RxNorm normalized name: clonidine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection clonidine 150 mcg
Trial: 21510527
Drug: Injection midazolam
RxNorm normalized name: midazolam Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection midazolam 5 mg
Trial: 2246712
Drug: HCl supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCl supplementation (0.01-0.02 ml of 1 N HCl/ml of milk)
Trial: 6352793
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous treatment
Trial: 6352793
Drug: Traditional intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional intensive insulin therapy
Trial: 31248268
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (new users)
Trial: 23129559
Drug: Mindfulness‐based Art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness‐based Art Therapy (MBAT)
Trial: 20558922
Drug: Miglitol 75
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 75 mg per meal
Trial: 20558922
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg per meal
Trial: 18259090
Drug: aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin + propranolol
Trial: 16973686
Drug: Strict rate
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict rate control (AFFIRM) aiming for resting heart rate <=80 bpm and heart rate during daily activity <=110 bpm
Trial: 6241559
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (30 micrograms ethinyl estradiol and 150 micrograms levonorgestrel)
Trial: 6241559
Drug: Progestin-only preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin-only preparation (75 micrograms dl-norgestrel)
Trial: 31713723
Drug: Ubiquinol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol 400 mg/day for 3 months
Trial: 25054775
Drug: 2-month prednisolone
RxNorm normalized name: prednisolone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-month prednisolone treatment
Trial: 25054775
Drug: 6-month prednisolone
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month prednisolone treatment
Trial: 23421353
Drug: GHB (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (1, 2, 4, 6, 8, and 10 g/70 kg)
Trial: 23421353
Drug: Ethanol (12,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (12, 24, 48, 72, 96, and 120 g/70 kg)
Trial: 23421353
Drug: GHB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB and Ethanol (highest tolerated doses)
Trial: 16877376
Drug: SQ regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ regimen (half of the FSH dose required for follicular development)
Trial: 12826993
Drug: SSRI (sertraline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI (sertraline)
Trial: 12826993
Drug: Tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressant (nortriptyline)
Trial: 8862104
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler (MDI)
Trial: 8862104
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of salbutamol by MDI
Trial: 8862104
Drug: MDI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI therapy with supervision
Trial: 1623994
Drug: 4.0-cm contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0-cm contraceptive implant
Trial: 1623994
Drug: 2.5-cm contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-cm contraceptive implant
Trial: 6435371
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glibenclamide treatment
Trial: 28231835
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg/day)
Trial: 28231835
Drug: Glibenclamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5 mg bid to a maximal dose of 5 mg bid)
Trial: 24383441
Drug: Computer tablet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer tablet-based prenatal psychosocial assessment (e-screening)
Trial: 9250800
Drug: Early G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early G-CSF (filgrastim 5 microg/kg/d) from day 4 of IVAP
Trial: 9250800
Drug: Late G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late G-CSF (filgrastim 5 microg/kg/d) from day 15 of IVAP
Trial: 8342211
Drug: Experiential suicide
RxNorm normalized name: modified Ankara virus-mediated suicide gene delivery vector TG4023
DrugBank: TG4023 (DB06108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential suicide prevention program (7 weekly 2-hour meetings)
Trial: 3783203
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, low‐dose continuous prednisone, and tamoxifen (CMFp + T) for 12 months
Trial: 3783203
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year
Trial: 3783203
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment after mastectomy (observation)
Trial: 3783203
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy with CMFp + T
Trial: 3783203
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone with p + T
Trial: 3783203
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (CMFp + T) and observation
Trial: 27925651
Drug: 40 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg/d LNG
Trial: 27925651
Drug: 300, 600,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300, 600, or 1050 μg/d ATZ combined with 40 μg/d LNG
Trial: 27925651
Drug: ATZ in
RxNorm normalized name: ATZ
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ATZ in the dose range investigated
Trial: 24630348
Drug: Intramuscular botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular botulinum toxin A (BoNT‐A) injections (n = 23)
Trial: 17982194
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with vitamin D(3), VK(2), and EHDP
Trial: 7733075
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d., CBS 120 mg q.i.d. for 7 days
Trial: 7733075
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d. (without CBS)
Trial: 2282998
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg t.i.d. and 400 mg nocte for 6 weeks
Trial: 2282998
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg b.i.d. for 6 weeks
Trial: 28391418
Drug: Amoxicillin-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-containing quadruple therapy (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Trial: 28391418
Drug: Cefuroxime-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime-containing quadruple therapy (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Trial: 17426677
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of simvastatin and aspirin
Trial: 12759560
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg brotizolam (BRZ)
Trial: 11040171
Drug: Topical amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical amethocaine gel (1.5 g applied to the dorsum of either foot)
Trial: 11040171
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 g applied to the dorsum of either foot)
Trial: 1428312
Drug: Diclofenac (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (3 x 50 mg for 6 weeks)
Trial: 3553279
Drug: L-649,923
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-649,923
Trial: 27721995
Drug: Sensory Enrichment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Enrichment Therapy
Trial: 20016012
Drug: High-energy-density (HED)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy-density (HED) snack food (60g daily for 14 days)
Trial: 20016012
Drug: Low-energy-density (LED)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy-density (LED) snack food (60g daily for 14 days)
Trial: 18089623
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of sulodexide
Trial: 18089623
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of sulodexide
Trial: 17108871
Drug: Various medical
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various medical strategies for weight loss (dietary intervention, physical activity, behavior modification, pharmacotherapy, surgery)
Trial: 14604717
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral clorazepate dipotassium
Trial: 14604717
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravenous midazolam
Trial: 8810584
Drug: Large stimulus
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large stimulus (L)
Trial: 1430679
Drug: Combination thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination thrombolytic therapy (rt-PA and urokinase)
Trial: 1430679
Drug: Urokinase monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase monotherapy
Trial: 1430679
Drug: rt-PA monotherapy
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA monotherapy
Trial: 6374780
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg daily for five days a week)
Trial: 30187524
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose (D5W) injection, 5ml
Trial: 30187524
Drug: Corticosteroid (triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (triamcinolone acetonide) injection, 3ml mixed with 2ml normal saline
Trial: 17972359
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus selegiline 10 mg/day (5 mg bid)
Trial: 12955641
Drug: Single-dose liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose liposomal amphotericin B (L-AmB) 7.5 mg/kg
Trial: 10735688
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of mannitol, furosemide, and dopamine (group B)
Trial: 10735688
Drug: Intermittent doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent doses of diuretics (furosemide, bumetadine, and ethracrynic acid) and fluids (group A)
Trial: 8716750
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of morphine (CIM)
Trial: 8716750
Drug: Intermittent intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intramuscular injection of pethidine (IMP)
Trial: 4006549
Drug: Short-term intravenous
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intravenous naloxone administration
Trial: 30702403
Drug: Bleaching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching treatment with room temperature storage (21.04°C±3.13°C)